Advances in CAR T-Cell Therapy from ASH 2024

In this episode [08.08 minutes], Medicom’s correspondent Robert van den Heuvel talks with Medical Science Officer Dr Rachel Giles about 3 presentations about CAR T-cell therapy from the annual meeting of the American Society of Hematology (ASH 2024), held in San Diego, CA, USA, from 7-10 December 2024.

The topics discussed are:

1. High CR rates for novel CAR T-cell therapy in follicular lymphoma and DLBCL

The investigational CAR T-cell therapy AZD0486 was associated with high complete response (CR) rates in patients with relapsed or refractory follicular lymphoma or patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), supporting further exploration of the drug.

2. ATALANTA-1: Promising data for novel CAR T-cell therapy

The investigational CD19-directed CAR T-cell therapy GLPG5101 was associated with high response rates and a favourable safety profile in patients with relapsed or refractory non-Hodgkin lymphoma. The remarkable 7-day vein-to-vein time is a major asset of this upcoming treatment.

3. ZUMA-5: Curative potential of axi-cel in follicular lymphoma

Axicabtagene ciloleucel (axi-cel) was associated with durable responses and long-term survival in patients with relapsed or refractory indolent non-Hodgkin lymphoma. The 5-year outcomes of the phase 2 ZUMA-5 study were consistent with the 4-year outcomes, indicating that axi-cel is a highly effective, durable option in this population.

Enjoy listening!